Rovelizumab
Modify Date: 2024-04-06 09:20:00
Rovelizumab structure
|
Common Name | Rovelizumab | ||
|---|---|---|---|---|
| CAS Number | 339086-79-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RovelizumabRovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke[1]. |
| Name | Rovelizumab |
|---|
| Description | Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Rovelizumab 结合 CD18 并对 CD18 整合素复合物具有活性，包括 CD11b-CD18 异源二聚体[2]。 |
| References |
[1]. Jones R. Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6. |
| No Any Chemical & Physical Properties |